跳轉至內容
Merck
全部照片(1)

Key Documents

View All Documentation

1285931

USP

氟伐他汀 钠

United States Pharmacopeia (USP) Reference Standard

同義詞:

(3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid monosodium salt

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C24H25FNNaO4
CAS號碼:
93957-55-2
分子量：:
433.45
MDL號碼:
MFCD08063391
分類程式碼代碼:
41116107
PubChem物質ID:
329749905
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

fluvastatin

製造商／商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

[Na+].CC(C)n1c(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)c(-c2ccc(F)cc2)c3ccccc13

InChI

1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m0./s1

InChI 密鑰

ZGGHKIMDNBDHJB-RPQBTBOMSA-M

尋找類似的產品？ 前往 產品比較指南

相關類別

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Fluvastatin sodium USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Fluvastatin Capsules

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Satoshi Sakai et al.
Life sciences, 102(2), 98-104 (2014-03-25)
Cardiac hypertrophy is elicited by endothelin (ET)-1 as well as other neurohumoral factors, hemodynamic overload, and oxidative stress; HMG-CoA reductase inhibitors (statins) were shown to inhibit cardiac hypertrophy partly via the anti-oxidative stress. One of their common intracellular pathways is
Hongjun Zhu et al.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 34(5), 539-543 (2014-11-25)
To observe the effect of Liandouqingmai recipe (Chinese herbal medicine compound preparation) on the quality of life (QOL) and inflammatory reaction of patients with coronary heart disease (CHD). A total of 101 CHD patients were randomized into two groups: treatment
Lee-Won Chong et al.
BMC gastroenterology, 15, 22-22 (2015-04-19)
Non-alcoholic steatohepatitis (NASH) is associated with hepatic fibrogenesis. Despite well-known cholesterol-lowering action of statins, their mechanisms against NASH-mediated fibrogenesis remain unclear. This study aimed at investigating the in vitro and in vivo anti-fibrotic properties of fluvastatin (Flu). Palmitate (PA)-induced changes
Hege Pihlstrøm et al.
Transplantation, 98(11), 1219-1225 (2014-07-08)
Elevated symmetric dimethylarginine (SDMA) has been shown to predict cardiovascular events and all cause mortality in diverse populations. The potential role of SDMA as a risk marker in renal transplant recipients (RTR) has not been investigated. We analyzed SDMA in
Masaki Watanabe et al.
Drug metabolism and pharmacokinetics, 30(2), 198-204 (2015-05-21)
Since drug-drug interaction (DDI) can affect organic anion-transporting polypeptide (OATP) and cause clinical events, prediction of such DDI is important in early clinical development. Although statins are useful probes for OATP-mediated DDI, endogenous probes would be more practical for predicting

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務